Novel extrapancreatic effects of incretin

The hormonal factors implicated as transmitters of signals from the gut to pancreatic β‐cells are referred to as incretins. Gastric inhibitory polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) are incretins. In addition to the insulinotropic effects, we have shown, using the GIP receptor and GLP...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Yuichiro, Tsukiyama, Katsushi, Sato, Takehiro, Shimizu, Tatsunori, Fujita, Hiroki, Narita, Takuma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Proceedings of INCRETIN 2015, A Symposium Celebrating the 45th Anniversary of the Discovery of GIP, 29–31 July 2015, Vancouver, Canada. This publication has been supported by: The Local Organizing Committee of INCRETIN 2015
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854509/
https://www.ncbi.nlm.nih.gov/pubmed/27186360
http://dx.doi.org/10.1111/jdi.12495
_version_ 1782430237491986432
author Yamada, Yuichiro
Tsukiyama, Katsushi
Sato, Takehiro
Shimizu, Tatsunori
Fujita, Hiroki
Narita, Takuma
author_facet Yamada, Yuichiro
Tsukiyama, Katsushi
Sato, Takehiro
Shimizu, Tatsunori
Fujita, Hiroki
Narita, Takuma
author_sort Yamada, Yuichiro
collection PubMed
description The hormonal factors implicated as transmitters of signals from the gut to pancreatic β‐cells are referred to as incretins. Gastric inhibitory polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) are incretins. In addition to the insulinotropic effects, we have shown, using the GIP receptor and GLP‐1 receptor‐deficient mice, that GIP and GLP‐1 have direct actions on adipocytes and the kidney, respectively. Because GIP receptors and GLP‐1 receptors are differentially expressed in a tissue‐specific manner, GIP and GLP‐1 have specific physiological activities, and further comprehensive characterization of the extrapancreatic actions of GIP and GLP‐1 is anticipated, as dipeptidyl peptidase IV inhibitors activate both GIP and GLP‐1 signaling.
format Online
Article
Text
id pubmed-4854509
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-48545092016-05-16 Novel extrapancreatic effects of incretin Yamada, Yuichiro Tsukiyama, Katsushi Sato, Takehiro Shimizu, Tatsunori Fujita, Hiroki Narita, Takuma J Diabetes Investig Proceedings of INCRETIN 2015, A Symposium Celebrating the 45th Anniversary of the Discovery of GIP, 29–31 July 2015, Vancouver, Canada. This publication has been supported by: The Local Organizing Committee of INCRETIN 2015 The hormonal factors implicated as transmitters of signals from the gut to pancreatic β‐cells are referred to as incretins. Gastric inhibitory polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) are incretins. In addition to the insulinotropic effects, we have shown, using the GIP receptor and GLP‐1 receptor‐deficient mice, that GIP and GLP‐1 have direct actions on adipocytes and the kidney, respectively. Because GIP receptors and GLP‐1 receptors are differentially expressed in a tissue‐specific manner, GIP and GLP‐1 have specific physiological activities, and further comprehensive characterization of the extrapancreatic actions of GIP and GLP‐1 is anticipated, as dipeptidyl peptidase IV inhibitors activate both GIP and GLP‐1 signaling. John Wiley and Sons Inc. 2016-03-31 2016-04 /pmc/articles/PMC4854509/ /pubmed/27186360 http://dx.doi.org/10.1111/jdi.12495 Text en © 2016 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Proceedings of INCRETIN 2015, A Symposium Celebrating the 45th Anniversary of the Discovery of GIP, 29–31 July 2015, Vancouver, Canada. This publication has been supported by: The Local Organizing Committee of INCRETIN 2015
Yamada, Yuichiro
Tsukiyama, Katsushi
Sato, Takehiro
Shimizu, Tatsunori
Fujita, Hiroki
Narita, Takuma
Novel extrapancreatic effects of incretin
title Novel extrapancreatic effects of incretin
title_full Novel extrapancreatic effects of incretin
title_fullStr Novel extrapancreatic effects of incretin
title_full_unstemmed Novel extrapancreatic effects of incretin
title_short Novel extrapancreatic effects of incretin
title_sort novel extrapancreatic effects of incretin
topic Proceedings of INCRETIN 2015, A Symposium Celebrating the 45th Anniversary of the Discovery of GIP, 29–31 July 2015, Vancouver, Canada. This publication has been supported by: The Local Organizing Committee of INCRETIN 2015
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854509/
https://www.ncbi.nlm.nih.gov/pubmed/27186360
http://dx.doi.org/10.1111/jdi.12495
work_keys_str_mv AT yamadayuichiro novelextrapancreaticeffectsofincretin
AT tsukiyamakatsushi novelextrapancreaticeffectsofincretin
AT satotakehiro novelextrapancreaticeffectsofincretin
AT shimizutatsunori novelextrapancreaticeffectsofincretin
AT fujitahiroki novelextrapancreaticeffectsofincretin
AT naritatakuma novelextrapancreaticeffectsofincretin

Ejemplares similares